Do you know your PSMA-tracer? Variability in the biodistribution of different PSMA ligands and its potential impact on defining PSMA-positivity prior to PSMA-targeted therapy

Different PSMA-PET tracers exhibit distinct biodistribution patterns, leading to variations in tumor-to-background ratios (TBR) in reference organs such as the liver, parotid gland, and spleen. Patient selection for PSMA-directed radioligand therapy is currently based on a semiquantitative approach using the liver as a reference region in [<sup>68</sup>Ga]Ga-PSMA-11-PET. Thus, the use of alternative [<sup>18</sup>F]-labeled tracers may result in under- or overestimation of a patient's suitability for therapy. This highlights the importance of a comprehensive understanding of the differences in tracer-specific uptake behavior for accurate decisions regarding PSMA-expression levels. However, as the patient cohort in this study is at earlier disease stages, the generalizability of these findings to later-stage patients remains unclear and requires further investigation.

Authors

Institutions

Publication Details

Journal
EJNMMI Research
Published
2025-01-10
DOI
https://doi.org/10.1186/s13550-024-01190-7
Citations
6
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
9.11

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Do you know your PSMA-tracer? Variability in the biodistribution of different PSMA ligands and its potential impact on defining PSMA-positivity prior to PSMA-targeted therapy

Klaus Schomäcker, Markus Dietlein, Katrin Sabine Roth, Felix Dietlein et al.
6 citations
EJNMMI Research
Prostate Cancer Treatment and Research
9.11
article

Do you know your PSMA-tracer? Variability in the biodistribution of different PSMA ligands and its potential impact on defining PSMA-positivity prior to PSMA-targeted therapy

Klaus Schomäcker, Markus Dietlein, Katrin Sabine Roth, Felix Dietlein, Philipp Krapf, Anna‐Maria Fink, Carsten Kobe, Jasmin Weindler, Bernd Neumaier, Henning Weis, Alexander Drzezga, Jan Heilinger
article en
6 citations

Abstract

Different PSMA-PET tracers exhibit distinct biodistribution patterns, leading to variations in tumor-to-background ratios (TBR) in reference organs such as the liver, parotid gland, and spleen. Patient selection for PSMA-directed radioligand therapy is currently based on a semiquantitative approach using the liver as a reference region in [<sup>68</sup>Ga]Ga-PSMA-11-PET. Thus, the use of alternative [<sup>18</sup>F]-labeled tracers may result in under- or overestimation of a patient's suitability for therapy. This highlights the importance of a comprehensive understanding of the differences in tracer-specific uptake behavior for accurate decisions regarding PSMA-expression levels. However, as the patient cohort in this study is at earlier disease stages, the generalizability of these findings to later-stage patients remains unclear and requires further investigation.

EJNMMI ResearchVol. 15(1)
Boston Children's Hospital (US), Harvard University (US), Forschungszentrum Jülich (DE), University Hospital Cologne (DE)
Universitätsklinikum Köln
Good health and well-being
Openalex Percentile: Top 2%
Prostate Cancer Treatment and Research
9.11
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.